NEW YORK - OS Therapies Inc. (NYSE-A: OSTX), a biotechnology firm specializing in cancer immunotherapies with a current market capitalization of $45.8 million, has requested the U.S. Food and Drug ...

Ionis Pharmaceuticals IONS announced that the FDA has granted the Breakthrough Therapy designation to its pipeline candidate, ION582, for the treatment of Angelman syndrome (AS), a rare neurological ...

Taysha Gene Therapies (NASDAQ:TSHA) jumped ~39% on Thursday after the U.S. FDA granted its Breakthrough Therapy designation for the company's lead candidate TSHA-102 as a treatment for Rett syndrome, ...